Tecovirimat monohydrateProduct ingredient for Tecovirimat

The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980. However, there have been longstanding concerns that smallpox may be used as a bioweapon.^2,5 Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002.² It is effective against all orthopoxviruses, including vaccinia, cowpox, ectromelia, rabbitpox, monkeypox, and Variola (smallpox) virus.^1,4

Tecovirimat was approved by the FDA in July 2018 as the first drug ever approved to treat smallpox.^6,5 Tecovirimat was later approved by Health Canada in December 2021,⁷ followed by the approval from the European Commission in January 2022.⁹ Other than smallpox, tecovirimat is also indicated to treat complications due to replication of the vaccinia virus following vaccination against smallpox, and to treat monkeypox and cowpox in adults and children.⁸ Tecovirimat is available as both oral and intravenous formulations.¹⁰